Bain Capital Life Sciences Investors LLC purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,295,322 shares of the company's stock, valued at approximately $37,735,000. Upstream Bio accounts for about 4.4% of Bain Capital Life Sciences Investors LLC's holdings, making the stock its 8th biggest position. Bain Capital Life Sciences Investors LLC owned 4.28% of Upstream Bio as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. FMR LLC bought a new position in Upstream Bio during the 4th quarter valued at about $117,977,000. Wellington Management Group LLP bought a new position in shares of Upstream Bio in the fourth quarter valued at approximately $25,632,000. Alliancebernstein L.P. acquired a new position in shares of Upstream Bio in the 4th quarter worth approximately $18,270,000. Norges Bank bought a new stake in Upstream Bio during the 4th quarter worth approximately $16,440,000. Finally, Geode Capital Management LLC acquired a new stake in Upstream Bio during the 4th quarter valued at $5,973,000.
Upstream Bio Stock Performance
UPB traded up $0.15 during trading on Thursday, hitting $8.96. The company's stock had a trading volume of 227,944 shares, compared to its average volume of 326,201. The company's 50 day moving average price is $7.84. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
See Also
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
